The Medicines and Healthcare products Regulatory Agency has added a serious nerve disorder as a possible side effect to the AstraZeneca Covid-19 vaccine after a handful of cases were linked to the jab.
Guillain-Barre syndrome (GBS) itself is a rare nerve disorder that can cause paralysis, but recent data has shown the likelihood “of a possible association” to the vaccine
“has strengthened,” according to the regulatory agency.
Of the millions who have received the AstraZeneca vaccine
, there were 432 reports of GBS possibly stemming from the vaccine
. There were 50 similar cases reported for the Pfizer vaccine
In response, the agency has updated their information on AstraZeneca
’s jab to include GBS as a rare, but possible, side effect.
The decision follows the European Medicines Agency adding the nerve disorder as a potential side effect for the vaccine
The EMA’s decision was based on hundreds of reports of GBS possibly linked to the vaccine
, which is branded as Vaxzevria. The side effect, however, is still classified as very rare.
In the US, the Food and Drug Administration (FDA) previously listed GBS as a very rare side effect for the one-shot Johnson
& Johnson vaccine